Lupin Launches Suprax 400mg Tablets
Lupin Pharmaceuticals launches Suprax 400mg Tablets (Cefixime USP) in the US.
This line extension further extends the brand franchise of Lupin's flagship anti-infective brand Suprax (Cefixime for oral suspension 100mg/5ml and 200mg/5ml).
Suprax 400mg Tablets will help Lupin to further increase its share of the $450 Million antibiotic market for the treatment of urinary tract infections. It will also extend use of Suprax to the patient population of children of the age of 12 yrs and older.
"Suprax 400mg Tablets offers an additional value proposition to pediatricians by covering adolescent and teenage patient population. The incidence of urinary tract infections is high in children and pediatricians are the 5th largest specialty prescribing antibiotics for this indication. I expect Suprax 400mg Tablets to add substantial value to the Suprax franchise," said Vinita Gupta, President, LPI.
Suprax 400mg Tablets will be promoted by a 60 strong specialty pediatric sales force. Lupin is also evaluating additional options of reaching out to other specialty doctors. Its efforts will be supplemented by innovative promotional campaigns.
The Suprax brand basket now includes Suprax (Cefixime for oral suspension 100mg/5ml and 200mg/5ml and Suprax 400mg Tablets (Cefixime USP).